Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

36 / 39

Outline
• Next generation ALK TKI new SoC in 1st line
• The brain is the issue
• PFS improvement correlates with OS?
• Best upfront vs. options at PD
• Can we personalise treatment upfront?
• For instance is there any sequence?